CCIA
ANAB icon

Campbell & Co Investment Adviser’s AnaptysBio ANAB Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,368
Closed -$1.23M – 1051
2025
Q4 		$1.23M Buy
25,368
+7,087
+39% +$276K 0.06% 484
2025
Q3 		$560K Buy
+18,281
New +$420K 0.04% 681

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Campbell & Co Investment Adviser's ANAB Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of AnaptysBio (ANAB) in Q1 2026, closing a stake of 25,368 shares — an estimated $1.23M sold.

Campbell & Co Investment Adviser first reported a position in ANAB in Q3 2025 and held it in 2 quarters. The position peaked at $1.23M in Q4 2025. 208 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining AnaptysBio position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 25,368 AnaptysBio shares in Q1 2026, an estimated $1.23M.
  • Campbell & Co Investment Adviser first reported a position in AnaptysBio in Q3 2025 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's AnaptysBio position peaked at $1.23M in Q4 2025.
  • 208 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.